ICIs target inhibitory receptors, known as checkpoints, present on the surface of lymphocytes (CTLA-4, PD-1) or their ligands (PD-L1) on the surface of tumor cells to prevent tumor escape, activate the antitumor response, and induce tumor regression.13 Here, CTLA4 is linked to neoplasm.